MILWAUKEE, Dec. 2, 2019 /PRNewswire-PRWeb/ -- Registration is now open for the American Society of Gene & Cell Therapy's (ASGCT) 23rd Annual Meeting, which will be held at the Hynes Convention Center May 12-15, 2020, in Boston. The meeting is the premier event in the field of gene and cell therapy and brings together scientists, physicians, patient advocates, and other stakeholders with the goal of advancing gene and cell therapies to alleviate human disease.
The 23rd Annual Meeting is expected to be the Society's largest ever, and attendees are encouraged to register early and to reserve their hotel rooms as soon as possible as the latter will sell out well before the meeting. An early registration discount is available through April 10, and groups of five or more are eligible for an additional discount. Pre-Meeting Workshops and the Closing Night Reception can be added to annual meeting registration.
Abstract submission for the 23rd Annual Meeting is now open and runs through January 29. International attendees can generate invitation letters online to apply for a VISA immediately after registering or submitting an abstract. More information about registration is available on the annual meeting website.
Hotel blocks for the Sheraton Boston Hotel and Boston Marriott Copley Place are also available now. ASGCT room blocks historically sell out months before the annual meeting, and once the ASGCT block is completely full, there's no guarantee attendees will be able to get the same room rate during the meeting.
More details about annual meeting programming will be posted on the website as they are confirmed. For any questions about the annual meeting, please contact mailto:[email protected] [[email protected] __title__ ].
About ASGCT The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.
SOURCE American Society of Gene & Cell Therapy
Advertisement
The 23rd Annual Meeting is expected to be the Society's largest ever, and attendees are encouraged to register early and to reserve their hotel rooms as soon as possible as the latter will sell out well before the meeting. An early registration discount is available through April 10, and groups of five or more are eligible for an additional discount. Pre-Meeting Workshops and the Closing Night Reception can be added to annual meeting registration.
Advertisement
Abstract submission for the 23rd Annual Meeting is now open and runs through January 29. International attendees can generate invitation letters online to apply for a VISA immediately after registering or submitting an abstract. More information about registration is available on the annual meeting website.
Hotel blocks for the Sheraton Boston Hotel and Boston Marriott Copley Place are also available now. ASGCT room blocks historically sell out months before the annual meeting, and once the ASGCT block is completely full, there's no guarantee attendees will be able to get the same room rate during the meeting.
More details about annual meeting programming will be posted on the website as they are confirmed. For any questions about the annual meeting, please contact mailto:[email protected] [[email protected] __title__ ].
About ASGCT The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.
SOURCE American Society of Gene & Cell Therapy
